Study Comparing the Efficacy and Safety of Zetomipzomib in Patients with Active Lupus Nephritis

• Research type

  Research Study

• Full title

  A Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis

• IRAS ID

  1007650

• Contact name

  Michelle Greenman

• Contact email

  palizade@kezarbio.com

• Sponsor organisation

  Kezar Life Sciences, Inc.

• Eudract number

  2022-502227-22

• Clinicaltrials.gov Identifier

  NCT05781750

• Research summary

  This is a Phase 2b, randomized, double-blind, placebo-controlled, global, multicenter study to evaluate efficacy and safety of zetomipzomib in patients with active Class III/IV +/-V LN or pure Class V.

• REC name

  North of Scotland Research Ethics Committee 1

• REC reference

  23/NS/0066

• Date of REC Opinion

  25 Aug 2023

• REC opinion

  Further Information Favourable Opinion